Fifty-nine companies raised $3.9 billion via IPOs in 1H14, compared to 26 that raised $1.5 billion in 1H13. The 1H14 group is up a median of 6% from their initial valuations, with the more recent deals seeing a bigger pop: the median increase for 2Q14 IPOs was 15% vs. 5% for the 1Q14 deals. Vital Therapies Inc. (NASDAQ:VTL) led the 2Q group, with a 127% increase in market cap. The company has a human liver cell-based extracorporeal liver assist device (ELAD) in Phase III testing to treat alcohol-induced